Drug Profile


Alternative Names: Bazedoxifene acetate; Bazedoxifeno; Brilence; Conbriza; TSE-424; Viviant; WAY 140424; WAY-TSE 424

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Ligand Pharmaceuticals; Wyeth
  • Developer Almirall S.A.; Ligand Pharmaceuticals; Pfizer
  • Class Azepines; Calcium regulators; Indoles; Osteoporosis therapies; Phenols; Small molecules
  • Mechanism of Action Selective estrogen receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Postmenopausal osteoporosis

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 07 Apr 2015 Bazedoxifene is still in Preregistration for Postmenopausal osteoporosis (Treatment and Prevention) in USA
  • 07 Apr 2015 Launched for Postmenopausal osteoporosis in Germany, Lithuania, Sweden, Croatia and Israel (PO) before April 2015
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top